On 19 June 2024, a subsidiary of Keysight Technologies, with its registered seat in Santa Rosa, California, USA, acquired all shares in AnaPico. Opfikon-based AnaPico develops and produces radio frequency (RF) and medium-wave (MW) test and measurement
Tags :Walder Wyss
UBS Switzerland successfully closed its issuance of covered bonds under its covered bond program in an aggregate principal amount of EUR 1.75 billion, consisting of EUR 1 billion 3.146% covered bonds due June 2031 and EUR 750 million floating rate
Walder Wyss advised Windyty on the acquisition of a majority stake in meteoblue. This acquisition marks a significant merger between two of the most innovative companies in the weather forecasting industry. Through this acquisition, the
Walder Wyss advised Enantios, an Eidgenössische Technische Hochschule Zürich (ETH) Zurich deep-tech Spin-off, on the completion of its seed financing round. The Enantios technology, developed over a five year research project at ETH
Walder Wyss advised Crédit Mutuel Equity, the international direct investment company of Crédit Mutuel Alliance Fédérale, in its Pacovis minority stake acquisition. As a result of a shareholder change
WalderWyss advised Klar on Bühlmann’s all shares acquisition. Vischer provided legal and tax advice to Dr. Roland P. Bühlmann and Marie-Thérèse Bühlmann in this transaction. Located in Schönenbuch (
Walder Wyss advised Helvetia on a successfully placed CHF 230 million senior bond with maturity in 2034 and a 1.95% coupon. The bond, guaranteed by Helvetia, will be used for general corporate purposes, including possible refinancings of outstanding
Walder Wyss advised Kanalservice Group, a portfolio company of Ufenau Capital Partners, on its acquisition of Roberit, Labosim Markierungs and Klose-Vital as part of the group’s ongoing growth strategy. Kanalservice Group is a full-service
On 23 May 2024, Houzy AG announced that Houzy and Devis.ch SA are merging. Walder Wyss advised Houzy Corporate/M&A with a team led by managing associates Dario Galli (pictured left) and Michael Kü
Walder Wyss advised SixPeaks Bio in securing USD 30 million in Series A financing led by founding investor Versant Ventures and a strategic collaboration with AstraZeneca. The latter, advised by Lenz & Staehelin, will provide additional,
